MP0250-a dual inhibitor of VEGF and HGF - plus bortezomib plus dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)

被引：0

作者：

Raab, M. S. ^{[1
]}

Ria, R. ^{[2
]}

Schlenzka, J. ^{[1
]}

Krahnke, T. ^{[3
]}

Haunschild, J. ^{[4
]}

Herrmann, F. ^{[4
]}

Fiedler, U. ^{[5
]}

Dawson, K. ^{[6
]}

Stumpp, M. T. ^{[7
]}

Mehr, K. Tadjalli ^{[4
]}

Harstrick, A. ^{[4
]}

Vacca, A. ^{[2
]}

Goldschmidt, H. ^{[1
]}

机构：

[1] Heidelberg Univ Hosp, Dept Haematol Oncol & Rheumatol, Heidelberg, Germany

[2] Univ Bari, Med Sch, Dept Biomed Sci & Human Oncol, Sect Internal Med, Bari, Italy

[3] Gogitars GmbH, Biostat, Heidelberg, Germany

[4] Mol Partners AG, Clin Dev, Schlieren, Switzerland

[5] Mol Partners AG, Preclin, Schlieren, Switzerland

[6] Mol Partners AG, Preclin Toxicol, Schlieren, Switzerland

[7] Mol Partners AG, CSO, Schlieren, Switzerland

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1041TiP

引用

页数：1

共 50 条

[21] Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Laubach, Jacob P.
Schjesvold, Fredrik
Mariz, Mario
Dimopoulos, Meletios A.
Lech-Maranda, Ewa
Spicka, Ivan
Hungria, Vania T. M.
Shelekhova, Tatiana
Abdo, Andre
Jacobasch, Lutz
Polprasert, Chantana
Hajek, Roman
Illes, Arpad
Wrobel, Tomasz
Sureda, Anna
Beksac, Meral
Goncalves, Iara Z.
Blade, Joan
Rajkumar, S. Vincent
Chari, Ajai
Lonial, Sagar
Spencer, Andrew
Maison-Blanche, Pierre
Moreau, Philippe
San-Miguel, Jesus F.
Richardson, Paul G.
LANCET ONCOLOGY, 2021, 22 (01): : 142 - 154
[22] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Morschhauser, Franck
Tilly, Herve
Chaidos, Aristeidis
McKay, Pamela
Phillips, Tycel
Assouline, Sarit
Batievi, Connie Lee
Campbell, Phillip
Ribrag, Vincent
Damaj, Gandhi Laurent
Dickinson, Michael
Jurczak, Wojciech
Kazmierczak, Maciej
Opat, Stephen
Radford, John
Schmitt, Anna
Yang, Jay
Whalen, Jennifer
Agarwal, Shefali
Adib, Deyaa
Salles, Gilles
LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
[23] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Duran, M.
Tombuloglu, M.
Tobu, M.
Vural, F.
Sahin, F.
Patir, P.
Uysal, A.
Saydam, G.
LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
[24] Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)
Chari, Ajai
Goldschmidt, Hartmut
Yang, Shiyi
Kosh, Michele
Delioukina, Maria
Qi, Ming
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E144 - E144
[25] Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial
Liu, Yanyan
Lin, Ningjing
Yi, Shuhua
Huang, Huiqiang
Guo, Ye
Zhang, Qingyuan
Yang, Haiyan
Zhang, Huilai
Zhang, Liling
Feng, Ru
Qian, Yijiao
Zhu, Jiankun
Song, Yuqin
Zhu, Jun
INTERNATIONAL JOURNAL OF CANCER, 2025,
[26] An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Vij, Ravi
Siegel, David S.
Jagannath, Sundar
Jakubowiak, Andrzej J.
Stewart, Alexander Keith
McDonagh, Kevin
Bahlis, Nizar
Belch, Andrew
Kunkel, Lori A.
Wear, Sandra
Wong, Alvin F.
Orlowski, Robert Z.
Wang, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 739 - 748
[27] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, Jesus F.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios Athanasios
Elghandour, Ashraf
Jedrzejczak, Wieslaw Wiktor
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Corradini, Paolo
Chuncharunee, Suporn
Lee, Je-Jung
Schlossman, Robert L.
Shelekhova, Tatiana
Yong, Kwee
Tan, Daryl
Numbenjapon, Tontanai
Cavenagh, Jamie D.
Hou, Jian
LeBlanc, Richard
Nahi, Hareth
Qiu, Lugui
Salwender, Hans
Pulini, Stefano
Moreau, Philippe
Warzocha, Krzysztof
White, Darrell
Blade, Joan
Chen, WenMing
de la Rubia, Javier
Gimsing, Peter
Lonial, Sagar
Kaufman, Jonathan L.
Ocio, Enrique M.
Veskovski, Ljupco
Sohn, Sang Kyun
Wang, Ming-Chung
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Corrado, Claudia
Bengoudifa, Bourras-Rezki
Binlich, Florence
Richardson, Paul G.
LANCET ONCOLOGY, 2014, 15 (11): : 1195 - 1206
[28] Efficacy and safety of pomalidomide and dexamethasone (Pd) for Chinese patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, single-arm, phase II study
Lu, J.
Fu, W-J.
Wang, Y-F.
Zhao, H-G.
Niu, T.
Fang, B-J.
Liao, A-J.
Bai, H.
ANNALS OF ONCOLOGY, 2021, 32 : S781 - S782
[29] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Avet-Loiseau, Herve
Casneuf, Tineke
Chiu, Christopher
Laubach, Jacob P.
Lee, Je-Jung
Moreau, Philippe
Plesner, Torben
Nahi, Hareth
Khokhar, Nushmia Z.
Qi, Ming
Schecter, Jordan
Carlton, Victoria
Qin, Xiang
Liu, Kevin
Wu, Kaida
Zhuang, Sen H.
Ahmadi, Tahamtan
Sasser, A. Kate
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[30] An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, Ravi
Wang, Michael
Kaufman, Jonathan L.
Lonial, Sagar
Jakubowiak, Andrzej J.
Stewart, A. Keith
Kukreti, Vishal
Jagannath, Sundar
McDonagh, Kevin T.
Alsina, Melissa
Bahlis, Nizar J.
Reu, Frederic J.
Gabrail, Nashat Y.
Belch, Andrew
Matous, Jeffrey V.
Lee, Peter
Rosen, Peter
Sebag, Michael
Vesole, David H.
Kunkel, Lori A.
Wear, Sandra M.
Wong, Alvin F.
Orlowski, Robert Z.
Siegel, David S.
BLOOD, 2012, 119 (24) : 5661 - 5670

← 1 2 3 4 5 →